There were significantly more patients with EGFR or ALK gene alteration in those treated with bevacizumab, likely reflecting potential efficacy of the bevacizumab-containing regimen (i.e., atezolizumab, bevacizumab, carboplatin, and paclitaxel) for the treatment of NSCLC with EGFR or ALK gene alteration [6,17]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.